The Gross Law Firm has issued a notice to ADMA Biologics shareholders regarding a securities class action, with a lead plaintiff deadline of August 10, 2026. The class period runs from August 9, 2024 to March 25, 2026. The complaint alleges that ADMA Biologics made false or misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. Shareholders who purchased ADMA shares during the class period are encouraged to contact the firm, though participation in any recovery does not require lead plaintiff appointment.
ADMA Biologics IncSecurities class action alleging false statements, undisclosed related party transaction, channel stuffing, and inadequate internal controls.